Drugs / INCB052793
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02265510 | Sep 2014 → Feb 2019 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03906344 | — | — | Incyte Corporation | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB052793 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03906344 ↗ |
| Action | Inhibit | “Novel JAK-inhibitor” NCT02265510 ↗ |
| Route | Oral | “INCB052793 tablets administered orally at the protocol specified dose strength and frequency.” NCT02265510 ↗ |